Significance of Hypoalbuminemia in the Development of Thromboembolic Complications in Severe Cases of SARS-CoV-2 Coronavirus Infection.

COVID-19 Hypoalbuminemia Thromboembolic complications

Journal

Journal of clinical medicine research
ISSN: 1918-3003
Titre abrégé: J Clin Med Res
Pays: Canada
ID NLM: 101538301

Informations de publication

Date de publication:
Apr 2024
Historique:
received: 26 01 2024
accepted: 09 03 2024
medline: 8 5 2024
pubmed: 8 5 2024
entrez: 8 5 2024
Statut: ppublish

Résumé

The course of coronavirus disease 2019 (COVID-19) is associated with the progression of a wide range of complications, among which thrombosis and thromboembolism are of particular importance. The significance of hypoalbuminemia in the development of thromboembolic complications (TECs) in patients with a severe course of COVID-19 is currently under active discussion. The objective of our study was to evaluate the significance of hypoalbuminemia in the development of TECs in patients with severe SARS-CoV-2 coronavirus infection. In a single-center observational retrospective study, case histories of 1,634 patients with a verified diagnosis of SARS-CoV-2 coronavirus infection were analyzed. Patients were divided into two groups according to the presence of TECs: 127 patients with venous TECs constituted the main group and 1,507 patients, in whom the course of COVID-19 was not complicated by the development of TECs, constituted the comparison group. The patients with TECs were older, and the prevalence of arterial hypertension, coronary heart disease, chronic heart failure, chronic kidney disease, and diabetes mellitus was higher than that in the comparison group. A single-factor regression analysis showed that a decrease in albumin levels of less than 35 g/L is associated with an eightfold increase in the risk of developing TECs in patients with severe SARS-CoV-2 coronavirus infection (area under the curve (AUC): 0.815, odds ratio (OR): 8.5389, 95% confidence interval (CI): 4.5637 - 15.977, P < 0.001). The sensitivity of the method was 76.34%, and the specificity was 72.58%. The study revealed that hypoalbuminemia is a predictor of development of TECs in severe cases of SARS-CoV-2 coronavirus infection.

Sections du résumé

Background UNASSIGNED
The course of coronavirus disease 2019 (COVID-19) is associated with the progression of a wide range of complications, among which thrombosis and thromboembolism are of particular importance. The significance of hypoalbuminemia in the development of thromboembolic complications (TECs) in patients with a severe course of COVID-19 is currently under active discussion. The objective of our study was to evaluate the significance of hypoalbuminemia in the development of TECs in patients with severe SARS-CoV-2 coronavirus infection.
Methods UNASSIGNED
In a single-center observational retrospective study, case histories of 1,634 patients with a verified diagnosis of SARS-CoV-2 coronavirus infection were analyzed. Patients were divided into two groups according to the presence of TECs: 127 patients with venous TECs constituted the main group and 1,507 patients, in whom the course of COVID-19 was not complicated by the development of TECs, constituted the comparison group.
Results UNASSIGNED
The patients with TECs were older, and the prevalence of arterial hypertension, coronary heart disease, chronic heart failure, chronic kidney disease, and diabetes mellitus was higher than that in the comparison group. A single-factor regression analysis showed that a decrease in albumin levels of less than 35 g/L is associated with an eightfold increase in the risk of developing TECs in patients with severe SARS-CoV-2 coronavirus infection (area under the curve (AUC): 0.815, odds ratio (OR): 8.5389, 95% confidence interval (CI): 4.5637 - 15.977, P < 0.001). The sensitivity of the method was 76.34%, and the specificity was 72.58%.
Conclusion UNASSIGNED
The study revealed that hypoalbuminemia is a predictor of development of TECs in severe cases of SARS-CoV-2 coronavirus infection.

Identifiants

pubmed: 38715557
doi: 10.14740/jocmr5119
pmc: PMC11073384
doi:

Types de publication

Journal Article

Langues

eng

Pagination

164-169

Informations de copyright

Copyright 2024, Tarzimanova et al.

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Auteurs

Aida Tarzimanova (A)

Department of Faculty Therapy No. 2, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation.

Anna Bragina (A)

Department of Faculty Therapy No. 2, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation.

Anna Pokrovskaya (A)

Department of Faculty Therapy No. 2, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation.

Alexander Ivannikov (A)

Department of Faculty Therapy No. 2, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation.

Ekaterina Sokolova (E)

Department of Faculty Therapy No. 2, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation.

Igor Cherkesov (I)

Department of plastic surgery, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation.

Tatyana Safronova (T)

Department of Faculty Therapy No. 2, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation.

Tatyana Vargina (T)

Department of Faculty Therapy No. 2, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation.

Liubov Ponomareva (L)

Department of Faculty Therapy No. 2, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation.

Alyona Isaeva (A)

Department of Faculty Therapy No. 2, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation.

Karine Oganesyan (K)

Department of Faculty Therapy No. 2, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation.

Valery Podzolkov (V)

Department of Faculty Therapy No. 2, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation.

Classifications MeSH